Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1803 vs RLD2001-1 in Essential Hypertension
NCT06438172Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine, losartan and chlorthalidone in essential hypertension (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from baseline in sitting systolic blood pressure at 8 weeks. Started Mar 2024; status: completed.
02
Drugs
amlodipinelosartanchlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06438172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438172.